RecruitingNCT07585032
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Sponsor
Sahlgrenska University Hospital
Enrollment
20 participants
Start Date
Mar 31, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Eligibility
Min Age: 15 YearsMax Age: 80 Years
Inclusion Criteria1
- Insulinoma verified by pathology (often from EUS-FNB-sampling)
Exclusion Criteria3
- Patients unwilling to participate
- Patients unable to understand and obtain written informed conscent
- Severe comorbidity
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREEUS-RFA
Treatment of insulinoma by EUS-RFA
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07585032